Phenotypic features in MECP2 duplication syndrome: Effects of age

Sarika U. Peters1 | Cary Fu1 | Eric D. Marsh2 | Tim A. Benke3 |
Bernard Suter4 | Steve A. Skinner5 | David N. Lieberman6 |
Shannon Standridge7 | Mary Jones8 | Arthur Beisang9 | Timothy Feyma9 |
Peter Heydeman10 | Robin Ryther11 | Daniel G. Glaze4 | Alan K. Percy12 |
Jeffrey L. Neul1

1Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee
2Children’s Hospital of Philadelphia and Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
3University of Colorado School of Medicine, Aurora, Colorado
4Baylor College of Medicine, Houston, Texas
5Greenwood Genetic Center, Greenwood, South Carolina
6Boston Children’s Hospital, Boston, Massachusetts
7Cincinnati Children’s Hospital, Cincinnati, Ohio
8Oakland Children's Hospital, Oakland, California
9Gilette Children’s Specialty Healthcare, Saint Paul, Minnesota
10Rush University Medical Center, Chicago, Illinois
11Washington University School of Medicine, St. Louis, Missouri
12University of Alabama at Birmingham, Birmingham, Alabama

Correspondence
Sarika U. Peters, Department of Pediatrics, PMB 74, 230 Appleton Place, Vanderbilt University Medical Center, Vanderbilt Kennedy Center, Nashville, TN 37203-5721. Email: sarika.u.peters@vumc.org

Funding information
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Grant/Award Numbers: R01HD084500, U54HD061222

Abstract

Background: MECP2 Duplication syndrome (MDS) is a rare X-linked genomic disorder that is caused by interstitial chromosomal duplications at Xq28 encompassing the MECP2 gene. Although phenotypic features in MDS have been described, there is a limited understanding of the range of severity of these features, and how they evolve with age.

Methods: The cross-sectional results of N = 69 participants (ages 6 months-33 years) enrolled in a natural history study of MDS are presented. Clinical severity was assessed using a clinician-report measure as well as a parent-report measure. Data was also gathered related to the top 3 concerns of parents as selected from the most salient symptoms related to MDS. The Child Health Questionnaire was also utilized to obtain parental reports of each child’s quality of life to establish disease burden.

Results: The results of linear regression from the clinician-reported measure show that overall clinical severity scores, motor dysfunction, and functional skills are significantly worse with increasing age. Top concerns rated by parents included lack of effective communication, abnormal walking/balance issues, constipation, and seizures. Higher levels of clinical severity were also related to lower physical health quality of life scores as reported by parents.

Conclusions: The data suggest that increasing levels of clinical severity are noted with older age, and this is primarily attributable to motor dysfunction, and functional skills. The results provide an important foundation for creating an MDS-specific severity scale highlighting the most important domains to target for treatment trials and will help clinicians and researchers define clinically meaningful changes.

KEYWORDS
gene duplication, pediatrics, phenotype
MECP2 Duplication syndrome (MDS [MIM: 300260]) is a rare X-linked genomic disorder, primarily affecting males, that is caused by interstitial chromosomal duplications at Xq28 encompassing the MECP2 gene (Van Esch et al., 2005). This gene encodes methyl CpG binding protein 2 (MeCP2), a critical regulator of neuronal gene transcription that is required for normal brain maturation (Chahrour et al., 2008; Horvath & Monteggia, 2018). Loss of MeCP2 function (under-expression) is the primary cause of Rett Syndrome (RTT), a distinct neurodevelopmental disorder primarily affecting females exhibiting some symptom overlap with MDS. The core clinical phenotype of MDS is related to over-expression of MeCP2, and involves infantile hypotonia, epilepsy, global developmental delays, choreiform movements, progressive spasticity and recurrent respiratory infections (Friez et al., 2006; Ramocki et al., 2009; Van Esch, 2012). Our prior studies reveal considerable variability in severity of many symptom domains within MDS including ambulation, hand function, and non-verbal communication (Ramocki, Tavyev, & Peters, 2010) that could be related to gene duplication size and content (Peters et al., 2019). Developmental regression occurs in approximately half of the population with highly variable age of onset (Cutri-French et al., 2020; Peters et al., 2013a). A comprehensive picture of the natural history and severity of MDS is needed as disease-modifying therapies may be possible, as demonstrated by the recent report of phenotypic reversal after antisense oligonucleotide treatment (ASO) in an animal model of MDS (Sztainberg et al., 2015).

While several studies have characterized the frequency of phenotypic features in MDS, there is a more limited understanding of how these features evolve with age, or of the range of severity of these specific features. This becomes problematic when developing clinical outcome measures. In fact, translational (mouse to human clinical applications) studies often fail because of a lack of consensus regarding common measures, an inability of available measures to assess a broad functional range, limited standardization and floor effects, and/or an absence of direct-observation measures or validated biomarkers (Berry-Kravis et al., 2018; Gold, Krishnaraj, Ellaway, & Christodoulou, 2017; Kaufmann, Stallworth, Everman, & Skinner, 2016). Before consensus can be reached regarding the best possible outcomes/measures to target, however, a basic understanding of disease progression inclusive of ranges of severity and the breadth of phenotypes is required. In fact, the FDA’s roadmap to patient-focused outcome measurement in clinical trials suggests that an understanding of the natural history/disease course as well as the impact of the disease is a crucial first step to outcome measure development. As such, in this paper, we present cross-sectional results of a natural history study in MDS showing clinical severity across a range of ages on a clinician-report measure as well as a parent report measure. We also present data related to parental reports of each child’s quality of life to establish disease burden.

Understanding differences in how the most important features of MDS vary with age will assist with planning for clinical trials. More specifically, this approach will help with future instrument development by identifying the most salient domains for assessment in MDS, and possible items that would change over time.
2.2.2 | Parent rating of overall functioning

Parents are asked to rate their child’s overall level of functioning over the past 6 months using an ordinal scale from 1 (Much improved) to 5 (Much worse). This rating is based on an overall opinion of function, inclusive of cognitive and physical/motor functioning as well as the impact of co-morbidities such as seizures.

2.2.3 | Parental top concerns

Parents are asked to select their top three concerns for their child over the past 6 months from a list of options containing symptoms relevant to MDS (e.g., lack of effective communication, frequent infections, seizures, constipation, lack of effective chewing or swallowing, teeth grinding, problems with sleep, abnormal walking/balance issues, repetitive hand movement, poor weight gain, reflux, anxiety, and scoliosis) as well as the opportunity to select “Other” and freely text the concern not listed on the preexisting list.

2.2.4 | Child health questionnaire—(parent-rating)

The child health questionnaire (CHQ) version that was utilized in this study is a parent-reported health-related quality of life measure. This measures 14 unique physical and psychosocial concepts and results in two overall summary scaled scores; a physical health score, and a psychosocial health score. Higher scores reflect a “better” quality of life. This measure has been used in previous studies of individuals with RTT (Barnes et al., 2015), as well as many studies of other genetic and metabolic rare diseases.

2.3 | Cytogenetic and molecular analyses

All participants were required to have a documented MECP2 duplication for entry into the study, verified by the local sites by review of the original genetic analysis report. Genetic analyses were performed by a variety of laboratories depending upon where the participant was originally diagnosed (e.g., Baylor College of Medicine, University of Chicago, Signature Genomics, Greenwood Genetic Center, Athena, CHOP, Emory, Gene Dx, Duke, etc.). Most participants had their duplications detected via Array Comparative Genomic Hybridization (Array-CGH), while others (mostly older participants) had Multiplex-Ligation-dependent Probe Amplification (MLPA).

2.4 | Analytic approach

Because prior studies have demonstrated the possibility of age-dependent changes in phenotypic features (Miguet et al., 2018; Peters, Hundley, Wilson, Carvalho, et al., 2013), simple linear regressions were performed to examine the degree to which age related to scores on the clinician-reported measure. The parent rating of overall functioning is an ordinal scale, and thus an analysis of variance (ANOVA) was conducted with parent rating as the independent variable, and age (which is a continuous variable) as the outcome variable. Parental top concerns are reported as weighted percentages. The weighting was calculated based on whether the parent rated their concern as first (1/1), second (2/3), or third-most important concern (1/3). To begin to gauge the impact of disease burden, a simple linear regression was performed to examine the degree to which overall R-MBA scores changed with ratings of parental quality of life for both physical health and social health scores. As a follow-up, correlations were examined between R-MBA subscales and the physical and social health quality of life scores.

3 | RESULTS

3.1 | Demographics

Sixty-nine participants have enrolled in this study to date (7 females and 62 males). The average age of participants at baseline was 9.45 years (SD = 7.78 years). All participants in this study lived at home. At baseline visit 28 participants had epilepsy. The average age of seizure onset was 8.96 years (SD = 5.83 years), and those who had seizures within the past 6 months were significantly older (n = 15.98 years; SD = 7.61 years) as compared to those without (n = 4.98 years; SD = 3.71 years) [F(1,68) = 63.85; p < 0.001]. Twenty-two percent (n = 15 of 69 total) of the participants had regressed at the time of their visit, and average age of regression was 10.38 years (SD = 7.72 years). Additional clinical characteristics of this population with regard to frequency of individual symptoms as well as duplication size have been reported elsewhere (Peters et al., 2019).

3.2 | Clinician-reported measure

A simple linear regression was conducted to determine how overall R-MBA scores change by age [F(1,68) = 10.122; p = 0.002]; R² = 0.13. Figure 1 displays a scatterplot of R-MBA scores by age and indicates increasing severity of scores with increasing age. Next, analyses were conducted examining differences in R-MBA subscales. Results revealed that Motor Dysfunction subscale (Figure 2) scores worsen with increasing age [F(1,68) = 16.53; p = 0.009]; R² = 0.20. Scores on the Functional Skills (Figure 3) subscale also worsen with increasing age [F(1,68) = 3.77; p = 0.05]; R² = 0.053. More specifically, older participants had total R-MBA, Motor Dysfunction, and Functional skills subscale scores that reflect increased severity; the increase in severity with age on the R-MBA is primarily accounted for by the Motor Dysfunction Scale and, to a lesser degree, the Functional Skills scale. Scores on the social skills F(1,68) = 1.75; p = 0.19], aberrant behavior F(1,68) = 2.34; p = 0.13], or Rett-like behaviors F(1,68) = 0.773; p = NS] scales did not significantly change with increasing age.
3.3 | Parent rating of overall functioning

An ANOVA was conducted to examine how parent ratings of overall functioning change with the participant's age. The results revealed that parent ratings were related to age. Follow-up post-hoc tests using the Bonferroni correction revealed that parents of older children were significantly more likely to provide ratings that reflected either that their child’s functioning was unchanged or worse \[ F(3,66) = 6.96; p = 0.000 \]; \( R^2 = 0.21 \). The results are shown in Figure 4. An ANOVA was also conducted to examine the convergent validity of the parent ratings of functioning along with the clinician-reported measure (R-MBA), and results indicated that the parents who rated their children as “worse” had higher R-MBA scores \( M = 26.8, SD = 15.6 \), as rated by clinicians as compared to those who rated their children as having improved \( M = 19.03, SD = 8.79 \) \[ F = 3.87; p = 0.05 \].

3.4 | Parental top concerns

Figure 5 summarizes the results of parent-reported top concerns across the entire sample. The most commonly reported concern is lack of effective communication (18.5%). When examining the second most frequent concern, this was related to abnormal walking/balance issues (15.7%). A nearly equivalent number of parents rated constipation and seizures as the next concerns, followed by lack of effective chewing/swallowing, and frequent infections. Since prior studies have suggested that epilepsy significantly impacts the disease course/progression of MDS (Miguet et al., 2018), a more detailed analysis of parental top concerns was conducted for the subgroup \( n = 28 \) of participants who had active epilepsy. These results are also shown in Figure 5. Of these participants, 17 listed seizures as their top concern, while three others listed seizures as a second most frequent concern. This was followed by abnormal walking/balance issues, lack of effective communication, and constipation.

3.5 | Health-related quality of life

A simple linear regression was conducted to determine how parent ratings of their child’s quality of life correspond to R-MBA scores. Results for the physical health scale revealed that higher R-MBA total score predicted lower physical health quality of life score \[ F(1,68) = 17.35; p = 0.000 \]; \( R^2 = 0.30 \) (Figure 6). We did not find a significant relationship between R-MBA total score and social health quality of life score. Examining the correlations with R-MBA subscales revealed that better physical health quality of life scale scores are significantly correlated with lower severity on the Motor Dysfunction Scale \( r = -0.31; p = 0.04 \), functional skills \( r = -0.53; p = 0.000 \), social skills \( r = -0.37; p = 0.015 \), and Rett-behaviors \( r = -0.31; p = 0.042 \). A higher score on the Aberrant Behavior subscale is inversely correlated with lower social health quality of life scores \( r = -0.31; p = 0.04 \).
**DISCUSSION**

This study utilized the R-MBA (Raspa et al., in press) as a first step toward examining how clinician ratings of severity in MDS change with age, and how clinical severity corresponds to parent-reported quality of life for the child. We also examined parental reports of top concerns as related to specific phenotypic features that are commonly reported in MDS. These data are critical in future planning for clinical trials in terms of establishing potential primary and secondary endpoints for treatments. The results of this study demonstrated that older participants with MDS have higher levels of clinical severity overall as measured by the R-MBA. When examining specific subscales, results indicated that older participants were more likely to have increased severity with regard to motor dysfunction which, in this study, reflected bradykinesia, dystonia, scoliosis, and/or hypertonia/rigidity. Infantile hypotonia has been consistently documented in studies of MDS (Lim, Downs, Wong, Ellaway, & Leonard, 2017; Miguet et al., 2018; Peters et al., 2019; Van Esch, 2012), although less has been written regarding changes in motor skills with advancing age. Recent studies do suggest, however, that spasticity and scoliosis are common in MDS (Miguet et al., 2018), and this current study reports the likelihood that these phenotypic features will emerge with advancing age. As is consistent with a previous study (Miguet et al., 2018), spasticity typically involved the lower limbs, and in those participants who were able to walk, gait abnormalities were noted. These observations mirror findings in animal models of MDS where mice develop a progressive neurologic phenotype that includes spasticity and seizures (Jiang et al., 2013; Na et al., 2012) as they age.

Older participants with MDS were also more likely to have increased severity with regard to Functional Skills (i.e., regression in motor skills, regression in communication skills, difficulties with chewing and swallowing, etc.). Our previous studies have shown there
is a possibility of regression in MDS (Peters, Hundley, Wilson, Carvalho, et al., 2013) that occurs at a much older age as compared to RTT. Developmental regression is likely to coincide with the onset of epilepsy in MDS (Marafi et al., 2019), and both are increasingly likely as participants age (Marafi et al., 2019; Peters et al., 2019). A recent study indicated that epilepsy affected around 47% of participants with MDS, disproportionately affected those who were older, and it was treatment-refractory and consistent with epileptic encephalopathy in a high percentage of those cases (Marafi et al., 2019). Lennox–Gastaut Syndrome (LGS), a classic epileptic encephalopathy, was diagnosed in almost 25% of the sample. Further studies should be conducted to determine which participants with MDS are at increased risk for epilepsy, inclusive of epileptic encephalopathy, or whether it is likely that all individuals with MDS will acquire epilepsy as part of disease progression.

In addition to clinicians, parents and caregivers are important stakeholders in determining the most meaningful clinical symptoms and domains of clinical importance (Persaud, Desine, Blizinsky, & Bonham, 2019; Snure Beckman et al., 2019; Tsai, Schie mann, McCandless, Strong, & Bridges, 2018). As such, parental reports of clinical severity, as well as input regarding their top concerns were obtained as part of this study. Our results suggested that parental reports mirrored our findings from clinician ratings of overall severity in that parents of older participants were more likely to report increased severity. The results also suggested some convergent validity of the R-MBA with parents ratings. Results indicated that the top concerns as reported by parents, which reflected the most demanding symptoms as related to MDS that impacted daily life, mirrored some of the most common aspects of the phenotype. Parents expressed the most significant concerns as related to lack of effective communication, followed by abnormal walking/balance issues (inclusive of concerns about falling). The parental concerns related to movement mirror clinician ratings as related to Motor Dysfunction, and do indicate that changes to gait and coordination, especially as individuals age, are significant aspects of the phenotype in MDS. Additional significant concerns raised by parents included constipation, epilepsy, difficulties with chewing/swallowing, and frequent infections. It is important to note that top concerns seem to shift, depending upon whether or not a participant has epilepsy such that the presence or absence of epilepsy is a primary factor in determining day to day life and disease course. When a participant had epilepsy, this was listed as a top concern followed by abnormal walking/balance issues, lack of effective communication, and constipation. Future clinical trials in MDS will require standardized measures of clinical severity with content validity for MDS that can be applied by investigators across all study sites. Taken together, data from clinician ratings along with parental top concerns offer a starting point for determining the most salient domains and clinical features across the shifting age spectrum and a way to identify minimally clinically significant differences.

Our data also suggests that parental reports of a child’s quality of life (QOL) are significantly impacted by clinical severity. This is most pronounced as related to physical health quality of life; a significant proportion of the variance in physical health QOL was reflected in R-MBA scores. Data suggest that there is a lesser impact on social QOL, which, for the scale utilized that in the current study, assessed externalizing problem behaviors. This is consistent with previous findings that suggest that aggression and self-injurious behaviors are less common in MDS as compared to other neurodevelopmental disorders (Peters et al., 2013). Rather, more commonly reported behavioral concerns in MDS are related to, for example, repetitive behaviors, sensory issues inclusive of hyposensitivity to pain, social withdrawal, and/or decreased eye contact (Peters, Hundley, Wilson, Warren, et al., 2013). These aspects of the behavioral phenotype in MDS are important to consider in light of the fact that some existing, standardized behavior rating scales could miss salient aspects of the phenotype in MDS.

The current study has some limitations that should be addressed in future work. First of all, the data presented are cross-sectional. There is a need for longitudinal studies that predict changes in clinical severity and disease progression in MDS. In particular, studies should focus on following younger cohorts over a longer period of time to better ascertain the onset of epilepsy and epileptic encephalopathy, motor dysfunction, and developmental regression. In addition, given the few numbers of females enrolled in the current study (n = 7) direct statistical comparisons were not made between overall clinical severity scores and parental top concerns of males vs. females. In future studies, however, it will be important to determine whether females with MDS have a different developmental trajectory and disease progression so as to better develop personalized interventions. Some prior studies suggest that females with MDS are as severely affected as their male counterparts (San Antonio-Arce et al., 2016), while others suggest that they could possibly have a milder disease course (Scott Schwoerer et al., 2014) possibly accounted for by differences in X-inactivation skewing.

In summary, this study extended prior research by examining age-dependent features of the phenotype in MDS, highlighting top concerns from parents and how these correspond to clinician ratings of severity, and also placing the significance of these concerns within the
context of quality of life. These data provide an important foundation for creating an MDS-specific severity scale, highlighting the most important domains to target for treatment trials, and helping clinicians and researchers determine and define clinically meaningful changes for the purposes of clinical trials.

ACKNOWLEDGEMENTS
The investigators gratefully acknowledge the participants and families who took their time to contribute to this study. This project was funded by NIH R01HD084500 to SUP, and NIH U54HD061222 to AKP. The NIH Rare Diseases Clinical Research Network (RDCRN) Rett syndrome, MECP2 Duplication disorder, and Rett-related disorders Consortium (U54HD061222) is a part of the NCATS Rare Diseases Clinical Research Network (RDCRN). The RDCRN is an initiative of the Office of Rare Diseases Research (ORDR), NCATS, funded by NIH R01HD084500 to SUP, and NIH U54HD061222 to AKP (Conceptualization, Funding Acquisition, Investigation, Formal Analysis, Writing – Original Draft), CF (Investigation, Formal Analysis, Writing – Review and Editing), EDM (Investigation, Writing – Review and Editing), TB (Investigation, Writing – Review and Editing), BS (Investigation, Writing – Review and Editing), SAS (Investigation, Writing – Review and Editing), DNL (Investigation, Writing – Review and Editing), SS (Investigation, Writing – Review and Editing), MJ (Investigation, Writing – Review and Editing), AB (Investigation, Writing – Review and Editing), TF (Investigation, Writing – Review and Editing), PH (Investigation, Writing – Review and Editing), RR (Investigation, Writing – Review and Editing), DGG (Investigation, Writing – Review and Editing), AKP (Funding Acquisition, Investigation, Writing – Review and Editing), JLN (Conceptualization, Methodology, Investigation, Funding Acquisition, Writing – Review and Editing).

DATA AVAILABILITY STATEMENT
Data Availability Statement: The de-identified data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Sarika U. Peters https://orcid.org/0000-0001-7439-5402
Bernard Suter https://orcid.org/0000-0002-0127-7322

REFERENCES
Persaud, A., Desine, S., Blizinsky, K., & Bonham, V. L. (2019). A CRISPR focus on attitudes and beliefs toward somatic genome editing from stakeholders within the sickle cell disease community. Genetics in Medicine, 21(8), 1726–1734. https://doi.org/10.1038/s41436-018-0409-6


---